This technology is a radiolabeled microtubule binding agent that enables positron emission tomography (PET) imaging of microtubules in the brain for diagnosis and treatment monitoring of tumors and neurological disease.
Microtubule dysregulation is associated with many diseases including cancer and neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and ALS, making them an important diagnostic and therapeutic target. PET is a non-invasive molecular imaging technique currently used for in vivo imaging. Although this imaging technique is powerful, imaging the brain is challenging because the radiotracers used must be capable of crossing the blood brain barrier (BBB). There are currently no PET tracers available for the in vivo imaging of microtubules in the brain.
This technology identifies high affinity microtubule-binding agents that can be radiolabeled with carbon-11 (11C) or fluorine-18 (18F). These agents are small enough to penetrate the BBB and be used for radiolabeling microtubules in the central nervous system (CNS) and other parts of the body. These radiolabeled microtubule binding agents enable live in vivo PET and single photon emission computed tomography (SPECT) imaging that can be used to look at tumors, neuropsychiatric, and neurodegenerative disorders.
[11C]MPC-6827 was synthesized and shown to cross the BBB and distribute rapidly to multiple brain regions in imaging studies.
IR CU17295
Licensing Contact: Jerry Kokoshka